SURFSurface Oncology, Inc.

Nasdaq surfaceoncology.com


$ 1.08 $ -0.01 (-0.93 %)    

Thursday, 07-Sep-2023 15:53:26 EDT
QQQ $ 426.27 $ 6.25 (1.49 %)
DIA $ 385.03 $ 2.65 (0.69 %)
SPY $ 505.65 $ 5.93 (1.19 %)
TLT $ 89.02 $ 0.03 (0.03 %)
GLD $ 214.96 $ -0.53 (-0.25 %)
$ 1.07
$ 1.05
$ 0.00 x 0
$ 0.00 x 0
$ 1.02 - $ 1.08
$ 0.56 - $ 1.43
1,510,170
na
64.97M
$ 1.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-02-2023 06-30-2023 10-Q
2 05-04-2023 03-31-2023 10-Q
3 03-09-2023 12-31-2022 10-K
4 11-02-2022 09-30-2022 10-Q
5 08-03-2022 06-30-2022 10-Q
6 05-09-2022 03-31-2022 10-Q
7 03-02-2022 12-31-2021 10-K
8 11-04-2021 09-30-2021 10-Q
9 08-05-2021 06-30-2021 10-Q
10 05-05-2021 03-31-2021 10-Q
11 03-09-2021 12-31-2020 10-K
12 11-10-2020 09-30-2020 10-Q
13 08-11-2020 06-30-2020 10-Q
14 05-12-2020 03-31-2020 10-Q
15 03-10-2020 12-31-2019 10-K
16 11-12-2019 09-30-2019 10-Q
17 08-07-2019 06-30-2019 10-Q
18 05-09-2019 03-31-2019 10-Q
19 03-07-2019 12-31-2018 10-K
20 11-13-2018 09-30-2018 10-Q
21 08-14-2018 06-30-2018 10-Q
22 05-29-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 surface-oncology-q2-eps-046-misses-034-estimate

Surface Oncology (NASDAQ:SURF) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(...

 synergy-of-coherus-and-surface-oncology-analyst-forecasts-50m-savings-and-2024-profitability

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.

 wedbush-downgrades-surface-oncology-to-neutral

Wedbush analyst Robert Driscoll downgrades Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.

 baird-downgrades-surface-oncology-to-neutral

Baird analyst Colleen Kusy downgrades Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.

 hc-wainwright--co-downgrades-surface-oncology-to-neutral-announces-5-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Surface Oncology (NASDAQ:SURF) from Buy to Neutral and ann...

 nasdaq-down-80-points-us-consumer-sentiment-surges-to-4-month-high-in-june

U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded ...

 why-squarespace-shares-are-trading-higher-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781.

 crude-oil-rises-adobe-posts-upbeat-results

U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded u...

 coherus-biosciences-microvision-millicom-and-other-big-stocks-moving-lower-on-friday

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in...

 us-stocks-mixed-dow-gains-50-points

U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday,...

 coherus-biosciences-acquires-small-immuno-oncology-player-surface-oncology-for-40m

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncol...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION